FDA Investigator Nicola M Fenty Stewart
Nicola M Fenty Stewart has conducted inspections on 19 sites in 6 countries as of 08 May 2017. See below for a list of the FDA enforcement documents resulting from those inspections.
Investigator Details
Number of Inspected Sites:
19
Last Inspection Date:
08 May 2017
Investigator Role:
FDA Investigator
Redica ID:
Countries of Inspections:
United States of America,
India,
France,
Canada,
Jordan,
Taiwan
FDA Investigators that have inspected at least one site in common with Nicola M Fenty Stewart:
Alanna L Mussawwir Bias,
Alexander M Kay,
Alia Legaux,
Allen F Hall,
Amalia C Himaya,
Amanda E Lewin, PhD,
Amy M Cramer,
Andrace L Deyampert,
Andrea A Branche,
Anita Narula, PhD,
Anita R Michael,
Anna M Brannen,
Anthony J Donato,
Arindam Dasgupta, PhD,
Barbara A Rusin,
Barbara Janine Breithaupt,
Barbara M Frazier,
Barry Cherney, PhD,
Bichsa T Tran,
Bo Chi, PhD,
Brien C Fox,
Camille D Brown,
Carla J Lundi,
Caryn M Mcnab,
CDR Rochelle B Young, RPh, MSA,
Cheron M Portee,
Christina C Santos,
Christina V Santos,
Comyar Shoghi,
Courtney N Long,
Craig A Garmendia,
Cynthia White,
Daniel L Aisen,
Daniel L Zheng,
Daniel W Cline,
David R Heiar,
Davinna Ligons, PhD,
Dawn C Olenjack,
Diane Cvan Leeuwen,
Doan T Nguyen, PharmD,
Donna Ltartaglino Besone,
Dr. Abhijit Raha, PhD,
Dr. Gopa Biswas, PhD,
Dr. Sriram Subramaniam, PhD,
Dr. Yubing Tang,
Esther C Broner, PhD,
Farhana Khan,
Frances Namuswe, PhD,
Frederick F Razzaghi,
Gajendiran Mahadevan, PhD,
Gene R Gunn,
George C Amedro,
Gerald Mierle,
Gerald N Mcgirl, DDS,
Gulshan R Anand,
Haley H Seymour,
Haroon Vohra (NMI),
Hasan A Irier, PhD,
Hector Jcolon Torres,
Himanshu Gupta, PhD,
Iris C Macinnes,
James Norman,
James R Fleckenstein,
Janete F Guardia,
Jee Chung, PhD,
Jeffrey P Raimondi,
Jennifer C Adams,
Jennifer Gogley,
Jennifer L Sheehan,
Jennifer M Gogley,
Jenny Sung,
Joel Welch, PhD,
John A Iwen,
John A Kadavil, PhD,
John R Myung,
Jonathan G Matrisciano,
Joseph L Despins, PhD,
Junho Pak,
Ka L Wong,
Kara A Scheibner, PhD,
Karen M Cooper,
Karen M Kondas,
Kathleen R Jones, PhD,
Kathryn A Krentz,
Kelvin Cheung,
Kelvin X Sanders,
Kendra A Biddick,
Kent A Conforti,
Kim Lthomas Cruse,
Kimberly A Dux,
Kip J Hanks,
Larry K Austin,
Laura E Garcia,
Laura Fontan, MS,
Laverne Puckett,
Lawrence Y Lee, PhD,
Leonard H Lavi,
Lequita M Mayhew,
Li Hongpaul Yeh, PhD,
Linda M Cheny,
Linda R Kuchenthal,
Lisa P Oakes,
Lori A Gioia,
Makini Cobourne Duval, PhD,
Marcia B Williams,
Marcus F Yambot,
Martin K Yau, PhD,
Matthew C Watson,
Maxyne T Lam,
Melkamu Getie Kebtie, PhD,
Michael F Skelly, PhD,
Michael Serrano,
Michelle A Marsh,
Michelle M Noe Varga,
Mihaly S Ligmond,
Mike M Rashti,
Mohsen Rajabi Abhari, FDA,
Nancy A Bellamy,
Nathan R Moon,
Nicholas Obiri, PhD,
Nicole M Bell,
Niraj R Mehta, PhD,
Omotunde O Osunsanmi,
Paul L Bellamy,
Paula J Bretz,
Paula M Laplant,
Peter R Lenahan,
Peter S Diak,
Rebecca Rodriguez,
Richmond K Yip,
Robert C Steyert,
Robert D Tollefsen,
Robert Darius,
Roger F Zabinski,
Rona Leblanc, PhD,
Ronald L Koller,
Ronda Leblanc,
Ruben C Ayala, PharmD,
Sam H Haidar, PhD,
Samantha J Pinizzotto, D V M,
Sandra S Saniga,
Sarah Arden,
Scott B Laufenberg,
Scott R Nichols, PhD,
Seongeun Cho (Julia), PhD,
Shirley H Isbill,
Sidney B Priesmeyer,
Sonia R Peterson,
Srinivas R Chennamaneni, PhD,
Sripal R Mada, PhD,
Stanley Au,
Stephanie Mangigian, MS/OSH, RN,
Stephenie M Ortiz,
Steven Fong, MS, PhD,
Stuart W Russell,
Suchan Kim,
Sunitha K Rajaram, PhD,
Susan D Yuscius,
Taichun Qin, PhD,
Tamika White,
Tawny L Colling,
Terri L Dodds,
Thao T Kwan,
Thao X Tran,
Thea C Grome,
Theressa B Smith,
Timothy C Grome,
Torrance J Slayton,
Tracey L Harris,
Uttaniti Limchumroon (Tom),
Xikui Chen (nmi), PhD,
Young M Choi, PhD,
Yumi J Hiramine,
Yvesna C Blaise,
Yvonne C Wilkes
Nicola M Fenty Stewart's Documents
| Publish Date | Document Type | Title |
|---|---|---|
| June, 2016 | FDA 483 | VIMTA LABS LIMITED - Form 483, 2016-06-17 |
| December, 2016 | FDA 483 | QPS, LLC - Form 483, 2016-12-16 |
| February, 2017 | FDA 483 | Amgen, Inc - Form 483, 2017-02-17 |
| November, 2016 | FDA 483 | International Pharmaceutical Research Center - Form 483, 2016-11-03 |
| June, 2015 | EIR | Labcorp Early Development Laboratories, Inc. - EIR, 2017-05-30 |
Experience Redica Systems’ NEW investigator profiles and dashboards
Redica Systems customers get access to over 1,400 FDA Investigator profiles, containing powerful analysis like:
- Total inspections conducted
- 483 rate
- OAI rate
- Warning Letter rate
- Inspections by Industry, Scope, and Inspection Reason
- And much more
Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.
Talk to sales to access our investigator profiles
Loading...
Investigator Profiles Are Just the Tip of the Iceberg
Becoming a Redica Systems customer not only provides you with unlimited access to profiles similar to the one above for every current and former FDA Investigator, but also grants you access to:
Inspection Intelligence
- Pre-Approval Inspection (PAI) trends
- The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
- Latest 483s: see what the trends are across all FDA Investigators
- CFR Heatmap: Citations aggregated by Subpart by Year
Vendor Intelligence
- Full inspection histories for your vendors down to the specific site level
- All of the functionality mentioned above but isolated to just your vendors
Regulatory Intelligence
- Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
- All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more